Antisense mRNA for NPY-Y1 receptor in the medial preoptic area increases prolactin secretion

Silveira, Narjara; Franci, Celso Rodrigues

doi:10.1590/s0100-879x1999000900016

Cited by 5 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NPY stimulates LHRH and LH release acutely, and this effect is dependent on the steroid mileu (40, 41). NPY has been shown to inhibit prolactin release in studies where injection of NPY Y1 receptor antisense mRNA into the medial‐preoptic area stimulates prolactin release (42). The apparently discrepant actions of orexin‐A in stimulating the HPA and HPG axes, whilst at the same time inhibiting prolactin release, could be explained by an increase in NPY, stimulated by orexin‐A, mediating these effects.…”

Section: Discussionmentioning

confidence: 99%

The Central Effects of Orexin‐A in the Hypothalamic‐Pituitary‐Adrenal Axis In Vivo and In Vitro in Male Rats

Russell

Small

Dakin

et al. 2001

J Neuroendocrinology

125

View full text Add to dashboard Cite

Orexin-A is synthesized in the posterolateral hypothalamus and immunoreactive fibres project to many central nervous system structures, including the paraventricular nucleus, which is rich in corticotropin releasing factor (CRF) neurones and neuropeptide Y (NPY) innervation. We investigated the central effects of orexin-A on the hypothalamic-pituitary-adrenal (HPA) axis by measuring plasma concentrations of corticosterone and adrenocorticotropic hormone (ACTH) in vivo. We explored the potential neuropeptide pathways involved by investigating the effects of orexin-A on CRF, NPY, arginine vasopressin (AVP) and noradrenaline release from hypothalamic explants in vitro. Intracerebroventricular (i.c.v.) injection of orexin-A (3 nmol) in male rats stimulated increases in plasma concentrations of corticosterone between 10 and 40 min after injection, and of plasma ACTH at 20 and 90 min after injection. Orexin-A significantly stimulated CRF and NPY release from hypothalamic explants in vitro. Orexin-A did not stimulate CRF release in the presence of the selective NPY Y1 receptor antagonist, BIBP3226. BIBP3226 alone did not alter CRF release from hypothalamic explants. Orexin-A had no effect in vitro on the release of other neuropeptides, AVP and noradrenaline, involved in the central regulation of the HPA axis. These results suggest that orexin-A is involved in activation of the HPA axis, and that these effects could be mediated via the release of NPY.

show abstract

Section: Discussionmentioning

confidence: 99%

The Central Effects of Orexin‐A in the Hypothalamic‐Pituitary‐Adrenal Axis In Vivo and In Vitro in Male Rats

Russell

Small

Dakin

et al. 2001

J Neuroendocrinology

125

View full text Add to dashboard Cite

show abstract

“…In accordance with our present results, previous reports indicate that prolactin release can be inhibited through NPY Y1 receptor activation. A recent study found that bilateral infusions of antisense to the Y1 receptor applied directly into the MPOA of ovariectomized rats resulted in a significant increase in plasma prolactin release with no concomitant effect on either LH or follicle-stimulating hormone release (23). Another study examined the effect that tuberoinfundibular (TIDA) NPY, synthesized in this area only during the lactational period, had on prolactin release from the pituitary.…”

Section: Discussionmentioning

confidence: 99%

Y1 Receptor Activation is Involved in the Effect of Exogenous Neuropeptide Y on Pup Growth and the Early Termination of Lactational Diestrus in the Postpartum Rat

Toufexis¹,

Yorozu²,

Woodside³

2002

J Neuroendocrinology

View full text Add to dashboard Cite

The effect of chronic administration of exogenous neuropeptide Y (NPY) and specific NPY receptor agonists and antagonists on reproductive function was examined in lactating rats. As previously demonstrated in our laboratory, chronic (7-day) intracerebroventricular (i.c.v.) NPY infusion (6 microg/day) from days 8-15 postpartum (pp) caused a significant decrease in milk production and an early termination of lactational diestrus. Similar application of the mixed Y1/Y4/Y5 receptor agonist (Leu31, Pro34) NPY (at 3, 6 and 9 microg/day) reproduced the effect of chronic NPY infusion on milk production in a dose-independent manner. Consistent with this effect, the potent Y1 antagonist/Y4 agonist, 1229U91, given concomitantly with NPY eliminated the decline in milk production. The Y2 receptor agonist, NPY13-36, had no effect on milk production at any of the doses used. Length of lactational diestrus was reduced following administration of the Y2 agonist at 18 microg/day but not at 9 microg or 27 microg/day whereas (Leu31, Pro34) NPY infusion had no effect on this parameter at any of the doses used. However, the group that was treated with NPY plus 1229U91 exhibited the usual length of lactational diestrus, indicating that there is at least some Y1 involvement in the effects of NPY on lactational infertility. To test the possibility that the effects of NPY infusion are mediated through changes in circulating prolactin and progesterone, plasma concentrations of these hormones were measured on day 15 pp in NPY-, (Leu31, Pro34) NPY- and vehicle-treated females. NPY-infused females had lower plasma prolactin concentrations than vehicle-infused dams but progesterone concentrations were similar across groups. Overall, these data indicate that chronic exogenous NPY-infusion in lactating females disrupts milk production and shortens lactational diestrus, most likely through reducing prolactin secretion, and that this effect is mediated via Y1 receptor activity.

show abstract

Chronic Neuropeptide Y Infusion during Lactation Suppresses Pup Growth and Reduces the Length of Lactational Infertility in Rats

Woodside

Beaulé

Lauay

2002

Hormones and Behavior

View full text Add to dashboard Cite

Antisense mRNA for NPY-Y1 receptor in the medial preoptic area increases prolactin secretion

Cited by 5 publications

References 23 publications

The Central Effects of Orexin‐A in the Hypothalamic‐Pituitary‐Adrenal Axis In Vivo and In Vitro in Male Rats

The Central Effects of Orexin‐A in the Hypothalamic‐Pituitary‐Adrenal Axis In Vivo and In Vitro in Male Rats

Y1 Receptor Activation is Involved in the Effect of Exogenous Neuropeptide Y on Pup Growth and the Early Termination of Lactational Diestrus in the Postpartum Rat

Chronic Neuropeptide Y Infusion during Lactation Suppresses Pup Growth and Reduces the Length of Lactational Infertility in Rats

Contact Info

Product

Resources

About